Neucardin®
Heart Failure with Reduced Ejection Fraction (HFrEF)
Key Facts
About Zensun Sci & Tech
Zensun Sci & Tech is a pioneering Chinese biotech with a 20+ year history, dedicated to discovering and developing original, first-in-class medicines. Its lead asset, Neucardin® (recombinant human neuregulin-1), is a novel biologic for heart failure that has received FDA Fast Track designation and is the centerpiece of a pipeline targeting cardiology and oncology. The company successfully raised approximately $76 million in funding, positioning it to advance its clinical programs and expand its global footprint through strategic research collaborations.
View full company profileAbout Zensun Sci & Tech
Zensun Sci & Tech is a pioneering Chinese biotech with a 20+ year history, dedicated to discovering and developing original, first-in-class medicines. Its lead asset, Neucardin® (recombinant human neuregulin-1), is a novel biologic for heart failure that has received FDA Fast Track designation and is the centerpiece of a pipeline targeting cardiology and oncology. The company successfully raised approximately $76 million in funding, positioning it to advance its clinical programs and expand its global footprint through strategic research collaborations.
View full company profileAbout Zensun Sci & Tech
Zensun Sci & Tech is a pioneering Chinese biotech with a 20+ year history, dedicated to discovering and developing original, first-in-class medicines. Its lead asset, Neucardin® (recombinant human neuregulin-1), is a novel biologic for heart failure that has received FDA Fast Track designation and is the centerpiece of a pipeline targeting cardiology and oncology. The company successfully raised approximately $76 million in funding, positioning it to advance its clinical programs and expand its global footprint through strategic research collaborations.
View full company profileAbout Zensun Sci & Tech
Zensun Sci & Tech is a pioneering Chinese biotech with a 20+ year history, dedicated to discovering and developing original, first-in-class medicines. Its lead asset, Neucardin® (recombinant human neuregulin-1), is a novel biologic for heart failure that has received FDA Fast Track designation and is the centerpiece of a pipeline targeting cardiology and oncology. The company successfully raised approximately $76 million in funding, positioning it to advance its clinical programs and expand its global footprint through strategic research collaborations.
View full company profileTherapeutic Areas
Other Heart Failure with Reduced Ejection Fraction (HFrEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | FDA Approved / PMA |
| ALLAY-HFrEF | Alleviant Medical | Pivotal Trial |
| Cardiac Contractility Modulation (CCM) Implant | Berlin Heals | Pre-clinical / Early Clinical |
| SRD001 (inferred) | Sardocor | Phase 1 |
| Undisclosed HFrEF Program | NanoPhoria Bioscience | Preclinical |
| AC01 | AnaCardio | Phase 2 |
| Firibastat | Quantum Genomics | Phase II |
| Omecamtiv Mecarbil | Cytokinetics | Phase 3 |